Skip to main content

Upper GI cancer surgery · UK

Oesophagectomy, done in a high-volume UK centre.

Oesophagectomy is major upper GI cancer surgery — and the UK is unusually clear about where it should be done. Centrally commissioned units, SBOTS-affiliated surgeons, a full MDT before the first incision, and honest talk about recovery.

See indicative pricing
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why patients choose us

  • 01

    A high-volume specialist centre, always

    Oesophagectomy is centrally commissioned in the UK — every case belongs in a unit doing more than twenty a year, with an SBOTS-affiliated surgeon.

  • 02

    The full MDT before the first incision

    Upper GI surgeon, oncology, radiology, pathology, endoscopist, dietician, physio and clinical nurse specialist — all in the room, weekly, before a plan is made.

  • 03

    Prehab that changes outcomes

    Exercise, nutrition, smoking and alcohol cessation, CPET fitness testing — arranged before neoadjuvant therapy, not scrambled after.

Indicative pricing

What a private oesophagectomy costs in the UK.

Indicative ranges across our partner high-volume centres. Send the details and we quote firm figures across two or three options.

In short

An Ivor Lewis in our network: £38,000–£58,000, with a 10–14 day stay.

Procedure Indicative range
Open Ivor Lewis oesophagectomy £38,000–£58,000
Minimally invasive oesophagectomy (MIO) £42,000–£62,000
Robotic-assisted oesophagectomy (RAMIE) £48,000–£68,000
Three-stage McKeown oesophagectomy £42,000–£65,000
Staging laparoscopy (pre-decision) £3,800–£5,800
Upper GI MDT review and second opinion £450–£850

Prices vary by centre, by which surgeon leads the case, by the approach (open, minimally invasive or robotic), and by whether adjuvant oncology sits inside or outside the surgical package. We come back with a firm quote within one working day.

The problem

The right centre, the right approach, the right team.

Oesophagectomy has one of the sharpest volume–outcome relationships in UK surgery. The centre and team matter as much as the operation itself.

  • Not sure of the plan?

    A second MDT read on staging, neoadjuvant choice and surgical approach — clearly explained, in writing.

  • Worried about recovery?

    CPET fitness, prehab and dietician input arranged before treatment starts, not chased afterwards.

  • Want it done properly?

    A centrally commissioned high-volume centre, an SBOTS-affiliated upper GI surgeon, and a full MDT — every time.

The journey

From staging to recovery — what happens, in order.

One clinical nurse specialist from first MDT to your post-op clinic — including the neoadjuvant window.

  1. 01

    Before

    Diagnosis and full staging

    EUS, CT, PET-CT and staging laparoscopy — every relevant investigation done before the MDT sits, not afterwards.

  2. 02

    Before

    The upper GI MDT decides

    Surgeon, oncology, radiology, pathology, dietician, physio and the clinical nurse specialist agree the plan together — surgery-first, CROSS chemoradiotherapy or peri-op FLOT.

  3. 03

    Before

    Neoadjuvant treatment and prehab

    CROSS (carboplatin, paclitaxel and 41.4Gy in 23 fractions) or peri-op FLOT for adenocarcinoma. In parallel: prehab, nutrition, CPET, smoking and alcohol cessation.

  4. 04

    On the day

    Admission and anaesthetic

    ERAS pathway from arrival. Thoracic epidural or paravertebral analgesia, arterial and central lines, and the anaesthetic team you have already met.

  5. 05

    On the day

    The oesophagectomy itself

    Ivor Lewis, McKeown, transhiatal or minimally invasive — chosen for your tumour, not the surgeon’s habit. Gastric conduit, careful anastomosis, feeding jejunostomy.

  6. 06

    On the day

    HDU or ITU, then the ward

    Overnight in a high-dependency bed. Chest drains, epidural, jejunostomy feeds. Sitting out on day one, walking within forty-eight hours.

  7. 07

    After

    Discharge, recovery and adjuvant care

    Home at eight to fourteen days. Portioned meals lifelong, six to twelve week recovery, and the oncology plan — adjuvant FLOT or nivolumab — starts on cue.

Typical end-to-end: 3–4 months from diagnosis to surgery when neoadjuvant treatment is used. Full recovery: 6–12 weeks after discharge.

When it helps

When an oesophagectomy is the right step.

The tumours and situations we see most, plus the red flag that deserves a two-week wait referral rather than a wait-and-see.

  • Adenocarcinoma of the lower oesophagus

    The commonest UK indication — often arising in Barrett’s, at or near the gastro-oesophageal junction.

  • Squamous cell carcinoma (SCC)

    Mid or upper oesophageal SCC — usually managed with CROSS chemoradiotherapy first, then a McKeown or Ivor Lewis resection.

  • Siewert I or II junctional tumours

    Gastro-oesophageal junction cancers — Siewert I and II are typically resected as an oesophagectomy rather than a gastrectomy.

  • High-grade dysplasia in Barrett’s

    When endoscopic resection is not enough — extensive high-grade dysplasia or intramucosal cancer that cannot be cleared endoscopically.

  • Recurrence after endoscopic therapy

    Barrett’s cancer that returns after endoscopic mucosal resection or radiofrequency ablation, where salvage surgery is the right step.

  • Selected benign strictures

    Rarely — end-stage caustic strictures or achalasia not amenable to endoscopic or motility surgery.

  • Oesophageal perforation, selected

    A small number of late-presenting or malignant perforations — decided by a specialist upper GI team, not in the emergency room.

  • Red flag: new dysphagia or weight loss

    Progressive difficulty swallowing solids, food sticking, or unexplained weight loss deserves a two-week wait upper GI referral — not a wait-and-see.

Surgical options

One operation, several ways to do it.

The approach is chosen for the tumour, the anatomy and the patient — not for the surgeon’s habit.

  • Two-stage Ivor Lewis

    Right thoracotomy and laparotomy with an intrathoracic anastomosis. The commonest UK approach for lower-third and Siewert I or II tumours.

  • Three-stage McKeown

    Right thoracotomy, laparotomy and a left neck incision with a cervical anastomosis. Preferred for mid or upper oesophageal tumours.

  • Transhiatal oesophagectomy

    No thoracotomy — the oesophagus is mobilised through the diaphragmatic hiatus and neck. Occasional use in selected cases and frail patients.

  • Hybrid minimally invasive

    Laparoscopic abdominal phase with an open thoracic phase — the MIRO trial approach. Fewer pulmonary complications than fully open surgery.

  • Totally minimally invasive (TMIE)

    Laparoscopic and thoracoscopic throughout. Equivalent oncological clearance and nodal harvest, with a smaller physiological hit.

  • Robotic-assisted (RAMIE)

    Robotic thoracic and abdominal phases. Growing UK adoption on the back of the ROBOT trial — steady expansion, similar oncology.

  • Gastric conduit reconstruction

    The stomach is tubularised to bridge the gap. Stapled or hand-sewn anastomosis, with a feeding jejunostomy as standard.

  • Salvage oesophagectomy

    Surgery after definitive chemoradiotherapy has failed to control disease — higher risk, still curative in the right patient.

Our vetted UK network

A small panel of upper GI centres, we picked them.

Centrally commissioned high-volume units across London, the South East, the Midlands and the North. Not listed publicly — introductions are made privately, once we understand your case.

Selection criteria

How we choose every centre and surgeon in our network.

A modern UK theatre set up for a minimally invasive oesophagectomy
Consultant-led upper GI
  • Centrally commissioned high-volume centres — more than twenty resections per year

  • SBOTS-affiliated consultant upper GI surgeons, not general surgeons doing occasional cases

  • Full upper GI MDT with dedicated oncology, radiology and clinical nurse specialist

  • Minimally invasive and robotic capability where the tumour and patient fit the approach

Safety and recovery

What to expect afterwards — honestly.

Oesophagectomy is major surgery. In a UK high-volume centre it is much safer than it used to be, but the recovery is real and the changes to how you eat are lifelong.

  • Mortality is 2–5% in high-volume UK centres

    A generation ago it was closer to ten percent. Centralisation and MDT working are why the numbers moved.

  • Anastomotic leak: 5–15%

    An intrathoracic Ivor Lewis leak is more consequential than a cervical one. Detected early with imaging and drained or stented.

  • Pulmonary complications are the big one

    Pneumonia, ARDS and empyema drive most of the morbidity. Prehab, epidural analgesia and early mobilisation blunt the risk.

  • Atrial fibrillation is common (20–30%)

    Usually short-lived and rate-controlled on the ward. Persistent AF is investigated for underlying anastomotic or septic causes.

  • Chyle leak and RLN palsy

    Chyle leak from the thoracic duct is uncommon but recognised. Recurrent laryngeal nerve palsy is more likely with a three-stage approach.

  • Conduit ischaemia is rare but catastrophic

    A failing gastric conduit needs urgent recognition and reoperation. High-volume teams are geared for it.

  • Portioned meals for life

    The new stomach is smaller and reflux-prone. Small frequent meals, sit up after eating, and expect 10–15% permanent weight loss.

  • Dumping and delayed gastric emptying

    Both are managed with dietary changes and, occasionally, prokinetics. The dietician follows you for at least a year.

  • Red flags after discharge

    Fever, chest pain, breathlessness, worsening dysphagia or heavy vomiting — call the surgical team, not the GP, and not tomorrow.

Reading your operation note

Your operation note in four parts. Read the last one first.

Whichever approach was used, the note the upper GI team sends you keeps to the same shape.

A UK upper GI surgeon reviewing a patient’s operation notes

A quiet reminder

Surgical and oncology language can read coldly — we translate it for you.

If you would like us to talk you through the note and the pathology report before your review, just ask.

  1. 01 Header

    Tumour, stage and neoadjuvant response

    Where the tumour was, its clinical stage, and whether CROSS or FLOT was given beforehand.

  2. 02 Technique

    Approach and reconstruction

    Ivor Lewis, McKeown, transhiatal or minimally invasive; the anastomosis site and technique; whether a feeding jejunostomy was placed.

  3. 03 Findings

    Nodal harvest and margins

    Number of lymph nodes retrieved, R0 or R1 status, and any intra-operative findings — including the pathologist’s Mandard tumour regression grade later.

  4. 04 Impression

    Recovery plan and adjuvant next steps

    Read this first: ITU or HDU stay, chest drain and jejunostomy plan, discharge timing, and whether adjuvant FLOT or nivolumab follows.

Recognised by major UK insurers

BupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealixBupaAXA HealthVitalityAvivaWPACignaHealix

Oesophagectomy is a covered procedure with all major UK insurers when clinically indicated. Neoadjuvant and adjuvant oncology is usually funded in parallel. We confirm cover — including the surgeon, anaesthetist and centre — before booking.

Frequently asked

Everything we get asked about an oesophagectomy.

Clear answers on centres, approach, neoadjuvant treatment, risks and life afterwards.

  • What is an oesophagectomy, and why might I need one?

    An oesophagectomy removes part or all of the oesophagus (the food pipe — spelled esophagus in the US) and rebuilds the swallowing tube with the stomach. In the UK it is done mainly for oesophageal cancer — adenocarcinoma at the gastro-oesophageal junction, squamous cell carcinoma of the middle or upper oesophagus, or Siewert I and II junctional tumours. Occasionally it is done for high-grade dysplasia in Barrett’s that cannot be cleared endoscopically.

  • Who decides whether I should have surgery?

    The upper GI cancer MDT — a weekly meeting of an upper GI surgeon, oncologist, radiologist, pathologist, endoscopist, dietician, physio and clinical nurse specialist. They review your EUS, CT, PET-CT and staging laparoscopy together and agree the plan. Nobody makes this decision alone.

  • Will I need chemotherapy or radiotherapy first?

    Almost always. For adenocarcinoma the standard is peri-operative FLOT chemotherapy (from the FLOT4 trial). For squamous cell carcinoma and many junctional cancers the CROSS regimen is used — carboplatin, paclitaxel and 41.4Gy of radiotherapy in 23 fractions before surgery.

  • Which surgical approach is best?

    It depends on where the tumour is. The two-stage Ivor Lewis (abdomen and right chest, intrathoracic anastomosis) is the commonest UK approach for lower-third and Siewert I or II tumours. Mid or upper tumours need a three-stage McKeown with a neck anastomosis. Minimally invasive and robotic approaches are increasingly used where the tumour and patient fit them — the MIRO and ROBOT trials showed fewer pulmonary complications with equivalent oncology.

  • Why does the choice of centre matter so much?

    Oesophagectomy is centrally commissioned in England — every centre must do more than twenty a year, with an SBOTS-affiliated surgeon and a full MDT. High-volume centres have brought mortality down from around ten percent historically to two to five percent today. It is the clearest volume–outcome relationship in UK surgery.

  • What is prehab, and does it really help?

    Prehab is structured exercise, nutrition, smoking and alcohol cessation before surgery, with a CPET fitness assessment. It measurably reduces pulmonary complications and shortens hospital stay. It runs alongside neoadjuvant treatment, not after it.

  • What are the main risks?

    Anastomotic leak (5–15%, more consequential with an intrathoracic Ivor Lewis), pulmonary complications, atrial fibrillation (20–30%), chyle leak, recurrent laryngeal nerve palsy (more common with McKeown), and — rarely but catastrophically — conduit ischaemia. Mortality is 2–5% in high-volume UK centres. Your team will quote your personal figure at consent.

  • What is life like afterwards?

    Hospital stay is eight to fourteen days, full recovery six to twelve weeks. You eat small, portioned meals for life, sit up after eating to control reflux, and expect ten to fifteen percent permanent weight loss. Some people get dumping syndrome or delayed gastric emptying; both are managed with diet and, sometimes, medication. A dietician follows you for at least a year.

WhatsApp Call us
Pulse Healthcare concierge

Send us your enquiry

A concierge service for UK private healthcare. We match you with the best vetted clinics and consultants in our network - they then contact you directly.

So we can match you to the right clinician close to you.

Confidential. We respond within one working day.